Lisdexamfetamine Renal Excretion and Caffeine Intake
Published pharmacokinetic and labeling information do not identify a clinically relevant interaction between dietary caffeine (e.g., coffee) and lisdexamfetamine (Elvanse/Vyvanse) exposure or renal excretion. [1]
Amphetamine exposure from lisdexamfetamine can be altered by drugs that change urinary pH, which can secondarily affect urinary excretion and blood levels of amphetamine. [1]
Pharmacokinetic Determinants of Lisdexamfetamine (Relevant to “Renal Excretion”)
Lisdexamfetamine is a prodrug that is converted to d-amphetamine systemically, with subsequent elimination of amphetamine primarily through renal excretion. [2]
In general, the fraction of amphetamine eliminated unchanged in urine is highly dependent on urinary pH, with greater unchanged urinary excretion under acidic conditions and less unchanged urinary excretion under basic conditions. [2]
Evidence on Caffeine Affecting Lisdexamfetamine or Amphetamine Pharmacokinetics
The US FDA prescribing information for lisdexamfetamine does not list caffeine/coffee as an interaction expected to change amphetamine blood levels or urinary excretion. [1]
No controlled pharmacokinetic study results were identified in PubMed that specifically tested coffee/caffeine intake as a modifier of lisdexamfetamine or amphetamine renal clearance/exposure. [2]
Urinary pH as the Clinically Actionable “Renal Excretion” Mechanism
Urinary pH–modifying agents are explicitly identified in prescribing information as capable of altering amphetamine blood levels by changing urinary excretion behavior. [1]
Renal excretion of weak bases (including amphetamine) is affected by urinary pH, with urinary alkalinization tending to reduce unchanged drug excretion. [3]
Monotherapy vs Combination “PK Modification” Scenarios
No lisdexamfetamine dose adjustment is recommended for caffeine intake in labeling. [1]
Dose adjustment is recommended when concurrent urinary pH–altering agents are used (acidifying vs alkalinizing agents), because these can increase or decrease amphetamine blood levels. [1]
Initiation and Monitoring Thresholds
Monitoring for altered tolerability or stimulant effects is clinically relevant when urinary pH–modifying agents are used concurrently, since amphetamine blood levels can change. [1]
Renal function–based dosing limits apply in severe renal impairment and ESRD and are independent of caffeine. [1]
Common Pitfalls to Avoid
Assuming caffeine intake is a driver of amphetamine renal clearance without evidence. [1]
Confusing the urinary pH interaction class effect (explicitly relevant to amphetamine exposure) with a non-specific “food/drink stimulant” effect. [1]
Practical Clinical Implication for Patients Taking Elvanse
Clinically meaningful changes in lisdexamfetamine exposure are most plausibly driven by renal function and concurrent urinary pH–altering agents rather than by routine caffeine/coffee intake. [1]